




























































Methods:	 This	 randomized,	 prospective,	 double-blinded,	 placebo-
controlled	 study	 was	 conducted	 on	 patients	 of	 either	 sex,	 American	
Society	 of	 Anesthesiologists	 (ASA)	 physical	 status	 I	 &	 II,	 undergoing	
elective	 surgeries	 requiring	 general	 anesthesia.	 The	 patients	 were	
randomly	divided	into	ondansetron	(A,	received	intravenous	ondansetron	
4	 mg)	 and	 placebo	 (B,	 received	 equivalent	 volume	 of	 normal	 saline)	
groups.	Manual	occlusion	of	venous	drainage	was	done	at	mid-arm	by	an	
assistant	for	1	minute	after	which	25%	of	the	calculated	dose	(2	mg/kg)	of	
propofol	 (1%	w/v	 in	 lipid	 base)	 was	 injected.	 Patients	 were	 asked	 by	 a	
blinded	investigator	to	score	the	pain	on	injection	of	propofol	on	4-point	





placebo	 group	 compared	 to	 the	 ondansetron	 group.	 (62.5%	 vs	 35.4%).	


















Propofol,	 a	 safe	 and	 smooth	 anesthetic	
inducing	 agent,	 has	 gained	 wide-spread	
popularity.2	 But	 pain	 during	 its	 injection,	
ranked	 an	 important	 problem	 in	 current	
practice	 of	 clinical	 anesthesia	 by	 American	
anesthesiologists3-4,	 ranges	 from	 28	 to	 90	
percent	 in	 adults.5-8	 Several	 methods	 have	
been	described	to	reduce	it,	but	none	of	them	
completely	 attenuate	 it.	 Propofol	 belongs	 to	
the	group	of	phenols	that	can	irritate	the	skin,	
mucous	 membrane,	 and	 venous	 intima.5-8	
Ondansetron,	 a	 5-HT3	 receptor	 antagonist,		
commonly	used	antiemetic	drug9	,	binds	to	the	
opioid	 μ	 receptors	 in	 humans	 and	 exhibit	
agonist	activity.9		As	a	result	of	its	multifaceted	
actions	 as	 a	 Na	 channel	 blocker,	 a	 5-HT3	
receptor	 antagonist,	 and	 µ	 opioid	 agonist,	













placebo-controlled	 comparative	 study	 was	
carried	 out	 at	 National	 Academy	 of	 Medical	
Sciences	 (NAMS)	 over	 the	 period	 of	 five	
months	 from	 August	 till	 December	 2017.	
Adults	 18-65	 years	 of	 age	 of	 either	 sex,	 ASA	
physical	 status1	 I	 or	 II,	 undergoing	 elective	
surgeries	 requiring	 general	 anesthesia	 were	
included	 in	 the	 study.	 Exclusion	 criteria	were	
patients	 with	 known	 allergy	 to	 study	 drugs,	
hemodynamic	 instability,	 who	 cannot	
communicate	 or	 speak,	 in	 whom	 IV	 access	
cannot	 be	 obtained	 in	 vein	 in	 the	 dorsum	of	
hand,	with	diabetes	mellitus	and	patients	with	
autonomic	 or	 peripheral	 neuropathy.	 Ethical	
approval	 was	 taken	 from	 the	 Institutional	
Review	Board	of	National	Academy	of	Medical	






that	 ondansetron	 reduces	 pain	 incidence	 to	
30%	with	alpha	and	beta	value	of	0.05	and	0.8	
respectively,	 we	 would	 need	 at	 least	 44	





the	 researchers,	 all	 eligible	 subjects	 were	
explained	 about	 the	 study	 and	 informed	















was	 assigned	 to	 the	 group	 accordingly.	 The	
drugs	 were	 prepared	 by	 the	 Anesthetist	 on	
duty	not	involved	in	the	study	according	to	the	
sealed	randomization	code,	only	accessible	to	
him.	 Study	 drugs	 were	 prepared	 in	 5	 ml	
identical	 syringes	 to	 make	 clear	 solutions	 of	
either	 4	 mg	 Ondansetron	 diluted	 in	 normal	




record	 in	 the	 log	book	the	administered	drug	
to	 the	 patient	 according	 to	 the	 sealed	
randomization	 code	 in	 case	 de-blinding	 was	
necessary.	Patient	and	the	primary	researcher	
anesthesiologist	 were	 unaware	 of	 the	
respective	groups.	
	
In	 the	 operation	 theatre,	 patients	 were	
attached	 to	 the	 standard	 monitors	 including	
pulse	oximeter,	noninvasive	blood	pressure,	3	








established	 with	 18-G	 cannula	 in	 a	 suitable	
vein	on	dorsum	of	non-dominant	hand	without	
any	 local	 infiltration	 and	 preloaded	 with												
15	ml/Kg	 of	 lactated	 Ringer	 solution	 over	 30	
mins.	 No	 analgesic	 drugs	 were	 given	 to	 the	
patient	before	injecting	propofol.		
	
The	 study	 drugs	 were	 then	 injected	
intravenously	 by	 the	 primary	 researcher	
anesthesiologist	 to	 the	 respective	 groups.	
Then	manual	occlusion	of	venous	drainage	was	
done	 at	 mid-arm	 by	 an	 assistant	 for	 1	 min.	
Then	 first	 25%	 of	 Propofol	 (1%	 w/v	 in	 lipid	
base)	 at	 2mg/kg	 dose	 was	 injected.	 Patients	
were	asked	standard	questions	about	the	pain	















Thereafter,	 induction	 of	 anesthesia	 was	




Data	 were	 represented	 as	 numerical	








Patient	 characteristics	 were	 comparable	
between	 the	 groups	 (Table	 2).	 No	 patients	





mild	 pain	 on	 propofol	 injection	 compared	 to	
placebo,	Table	3.	
	
Table	 2.	 Characterstics	 of	 patients	 in	 studying	 efficacy	 of	 prophylactic	 intravenous	 ondansetron	 for	
attenuation	of	pain	on	propofol	injection	
	
Variables		 Group	A	(ondansetron)	 Group	B	(placebo)	 p	Value	




Weight	in	Kg	(mean±SD)	 54.98±8.66	 57.15±9.26	 0.239	
ASA:		
					I	 29/48	 27/48	 0.679	
					II	 19/48	 21/48	
	
Table	 3.	 Incidence	 and	 severity	 of	 pain	 on	 propofol	 injection	 with	 or	 without	 prophylactic	 intravenous	
ondansetron	for	attenuation	of	pain		
	
		 Group	A	(Ondansetron)	 Group	B	(Placebo)	 p	value	
Pain	on	Propofol	injection	 17/48	(35.4%)	 30/48	(62.5%)	 0.008	
																											Mild		 14/48	(29.2%)	 2/48	(4.2%)	 0.001	
																											Moderate		 3/48	(6.2%)	 16/48	(33%)	 0.001	
																											Severe		 0	 12/48	(25%)	 0.000	











pretreatment	 with	 4	 mg	 of	 ondansetron	
significantly	decreased	the	incidence	of	pain	to	
35.4%.	 Two	 other	 studies	 with	 study	 design	
similar	 to	our	 study	 reported	 its	 incidence	of	




and	 hyperpermeability,	 increases	 the	 contact	
between	the	aqueous	phase	propofol	and	the	
free	 nerve	 ending,	 resulting	 in	 pain	 on	
injection.	 This	 pain	 has	 a	 10-20	 seconds	
delayed	onset.7,24	
	
Pharmacological,	 non-	 pharmacological	 or	 a	
combination	of	both	methods	have	been	used	
in	 the	 attenuation	 of	 pain	 due	 to	 propofol	
injection.	Some	of	them	are	pre-treatment	or	
addition	 of	 lidocaine13,15,20-22,24	 pre-treatment	
with	 ondansetron,11-13,15,17-19	 opioids	 as	
fentanyl22,	 administration	 of	 different	
formulas	 of	 propofol16,23	 that	 include	 long	
chain	 triglycerides	 (LCT)	 alone	 or	 medium-
chain	triglycerides	(MCT)	with	LCT,	mechanical	
interventions	such	as	different	infusion	rates24,	




An	 intravenous	 bolus	 injection	 of	 propofol	 in	
the	 antecubital	 fossa	 was	 the	 only	 approach	
that	 caused	 no	 pain.6,24	 When	 administered	
intravenously	 in	 the	 dorsum	of	 the	 hand	 the	




lower	 in	our	 study	 if	we	had	also	 chosen	 the	
veins	 in	 the	 antecubital	 fossa.	 However,	 the	
veins	 at	 the	 dorsum	 of	 hand	 are	 more	
convenient	 and	 accessible	 and	 is	 frequently	
used	 by	 anesthesiologists	 as	 unintentional	
extravasations	 of	 occluded	 IV	 lines	 in	 the	
elbow	may	go	unnoticed.	Slowing	 the	 rate	of	
injection	 caused	 the	 greatest	 discomfort.24			
When	propofol	is	injected	mid-stream	into	the	
lumen	of	the	vein,	the	larger	diameter	of	and	
faster	 flow	 rate	 will	 minimize	 the	 extent	 of	
propofol	 coming	 into	 contact	 with	 the	




when	 propofol	 was	 administered	 at	 a	
temperature	 of	 4°C.14	We	 	 could	 not	 control	
the	temperature	of	propofol	in	our	study	and	
patients	 received	 propofol	 at	 room	
temperature	 which	 may	 affect	 the	 incidence	
and	 severity	 of	 pain	 on	 propofol	 injection.	
However,	 one	 systematic	 review	 and	 meta-
analysis	 showed	 that	 cold	 propofol	 (4˚C),	
propofol	at	room	temperature,	and	modifying	
the	speed	of	the	intravenous	carrier	fluid	were	
non-effective	 interventions	 for	 reduction	 of	
pain	 on	 propofol	 injection.6	 This	 study	 also	
showed	 that	 pre-treatment	 with	 4	 mg	 of	
ondansetron	 significantly	 decreased	 the	
incidence	 of	 pain	 on	 propofol	 injection	 to	
35.4%.		
	
A	 similar	 study	 to	 ours	 showed	 significant	
reduction	in	the	incidence	of	pain	on	Propofol	
injection	 in	 the	ondansetron	group	from	60%	
to	 26.7%	 and	 lesser	 pain	 scores	 with	 the	
pretreatment	 of	 4	 mg	 IV	 ondansetron.11	
Similarly,	 in	 another	 	 study,	 the	 incidence	 of	
pain	 was	 significantly	 reduced	 on	 propofol	
injection	 in	 ondansetron	 group	 vs	 control	






had	 mild	 pain	 and	 only	 three	 of	 them	
complained	 of	 moderate	 pain,	 whereas,	 a	
significant	number	of	 patients	 in	 the	Placebo	
group	had	higher	degrees	of	pain	on	propofol	
injection,	 including	 25%	 with	 severe	 pain.	 A	
study	done	in	2012	showed	that	ondansetron	
pretreatment	 significantly	 decreased	 the	
incidence	 of	 propofol	 injection	 pain	 from	
82.2%	to	24.4%.18	Similar	to	our	study,	in	these	
studies,	propofol	has	been	given	on	the	veins	
of	 dorsum	 of	 hand	 and	 tourniquet	 applied	









fibers	 responsible	 for	 transmission	 of	 pain	
resulting	 from	 direct	 irritation	 of	 the	 blood	
vessel	 walls	 by	 propofol.10	 Furthermore,	






Some	 of	 our	 limitations	 are	 that	 factors	
affecting	 the	 incidence	 of	 pain	 as	 speed	 of	
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